Ikarian Capital, LLC Corvus Pharmaceuticals, Inc. Transaction History

Ikarian Capital, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.87 - $2.03 $443,809 - $1.04 Million	-510,126 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$1.46 - $2.48 $40,173 - $68,239	27,516 Added 5.7%	510,126 $837,000
Q4 2021 Feb 14, 2022	SELL	$2.34 - $5.31 $643,347 - $1.46 Million	-274,935 Reduced 36.29%	482,610 $1.16 Million
Q3 2021 Nov 15, 2021	BUY	$1.89 - $8.53 $1.24 Million - $5.61 Million	657,545 Added 657.55%	757,545 $3.67 Million
Q1 2021 May 17, 2021	BUY	$2.86 - $4.77 $286,000 - $476,999	100,000 New	100,000 $307,000

30.4M

1.06M

84.3K

Ticker CRVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,553,500
Market Cap $316M
Description
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.